RPL7P11

Across TCGA pan-cancer cohorts, RPL7P11 RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of RPL7P11’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where RPL7P11 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPL7P11 is over-expressed in tumor, although a few such as BRCA and PAAD show the opposite, repressed pattern.

LIHC, COAD, and BRCA are the cancer types where RPL7P11 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL7P11 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	All	All	+0.081	.002	6	view →
COAD	Female	II,III,IV	+0.303	<.001	5	view →
BRCA	All	IV	−0.315	.002	2	view →
PAAD	Male	All	−0.145	.010	2	view →
KIRC	All	All	+0.056	.027	2	view →
STAD	Male	IV	−0.295	.048	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

RPL7P11–LIHC

Open the LIHC breakdown →